Wird geladen...
Tivozanib in renal cell carcinoma: a new approach to previously treated disease
Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospecti...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Med Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7249546/ https://ncbi.nlm.nih.gov/pubmed/32547647 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920923818 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|